Bryophyllum pinnatum (syn. Kalanchoe pinnata), a plant native to Madagascar, was introduced into anthroposophic medicine in the early 20 th century. In recent years, a number of investigations were conducted on the chemical composition, pharmacological properties, and clinical efficacy of Bryophyllum. Here the phytochemistry, and pharmacological and clinical data are reviewed. With respect to pharmacology, a special focus was put on properties related to the use in anthroposophic medicine as a treatment for "hyperactivity diseases", including preterm labor, restlessness, and sleep disorders. Recent studies suggest that B. pinnatum has also potential as a treatment option in patients suffering from overactive bladder syndrome. Tolerability of Bryophyllum is addressed, and existing toxicological data are discussed in relation to bufadienolides contained in Bryophyllum. Open questions regarding the use of Bryophyllum are also discussed.
Bryophyllum pinnatum (Crassulaceae) is a perennial succulent herb that originated from Madagascar, and now occurs in tropical and subtropical regions throughout the world. In the traditional medicine of tropical countries, B. pinnatum is used for various purposes. In contrast, the utilization as a medicinal plant in Europe is more recent, and up to now was almost exclusively restricted to anthroposophic medicine. Bryophyllum was introduced in 1921 by Rudolf Steiner, the founder of anthroposophy, for the treatment of what at that time was designated as "hysteria". Meanwhile, the German Homeopathic Pharmacopeia (HAB) 2014 [1] lists B. pinnatum as officinal in its monograph "Bryophyllum Rh", and Bryophyllum preparations are used for a variety of hyperactivity disorders. Until very recently only very limited experimental and clinical data were available to support the use of B. pinnatum from a scientific viewpoint. Some years ago an interdisciplinary team of scientists joined forces in the so-called Bryophyllum Study Group (see acknowledgments), with the aim to establish sound clinical, pharmacological and chemical foundations for the use of B. pinnatum as a herbal medicine. In the following, we review the current state of knowledge on the phytochemistry, pharmacological properties, and clinical data on B. pinnatum, with a focus on the therapeutic uses in anthroposophic medicine, and research performed in the Bryophyllum Study Group.
Bryophyllum species are perennial succulent plants. The genus comprises some 25 species which are all native of Madagascar [2] , however, many are now introduced into other tropical areas. The genus has an intricate taxonomy which is still disputed by specialists [2] [3] [4] . Bryophyllum species have a unique mode of vegetative reproduction, whereby young plantlets develop on the edges of leaves before being shed for propagation. Bryophyllum pinnatum (Lam.) Oken, according to The Plant List [5] , has over 20 synonyms. Of these, Kalanchoe pinnata (Lam.) Pers. is frequently used in the literature. B. pinnatum grows up to 1.5 m in height and has numerous vernacular names, such as life plant, air plant, love plant, miracle leaf, cathedral bells, and Goethe plant [6] .
Phytochemistry of B. pinnatum:
A broad spectrum of secondary metabolites has been reported from the species, including bufadienolides, flavonoids, triterpenes, steroids, phenanthrenes, and some ubiquitous compounds.
Eight bufadienolides (1-8) have been identified from leaves, flowers, stems and roots of B. pinnatum ( Figure 1 ) [7] [8] [9] [10] . A characteristic structural feature is the 1,3,5-orthoacetate function which is present in some of the compounds. Bersaldegenin-1-acetate (1), bersaldegenin-1,3,5-orthoacetate (3), the glycoside bryotoxin A (7), and bryotoxin C (= bryophyllin A, 4) have been found in all Bryophyllum species that have been investigated so far. In contrast, minor bufadienolides 5 and 6 have been identified only in B. pinnatum. With the aid of UHPLC-MS/MS bufadienolides were recently quantified in different batches of leaves and pressed juices of B. pinnatum. Bryophyllin A (4), bersaldegenin-1-acetate (1), bersaldegenin-3-acetate (2), and bersaldegenin 1,3,5-orthoacetate (3) were found to be the major bufadienolides, with total contents in leaves ranging from 3.78 to 40.50 mg/100 g dry weight. Interestingly, when single leaves from individual plants were analyzed, a significantly higher content was found in younger leaves [11] .
Flavonoids are major metabolites in B. pinnatum, and include numerous flavonol derivatives , in particular, quercetin and kaempferol glycosides, and some flavones (31) (32) (33) (34) (35) (Figure 2 ) [7, [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] .
Other phenolic compounds reported from the aerial parts include phenanthrene derivatives, lignans, and phenolic acids, such as gallic acid, ferulic acid, syringic acid, caffeic acid, p-coumaric acid, protocatechuic acid, 4-hydroxy-3-methoxy-cinnamic acid, and 4-hydroxybenzoic acid [22, 23] . various phytosterols were reported in the leaves or the aerial parts [22] . B. pinnatum was shown to contain large amounts of malic acid [7] . Other carboxylic acids include oxalic acid, citric acid, isocitric acid, succinic acid, oxaloacetate, and phosphoenolpyruvate [22, 23] .
B. pinnatum in anthroposophic medicine: Anthroposophic medicine (AM) is an integrative, multimodal medical system that was developed by the Austrian philosopher Rudolf Steiner (1861-1925) and the Dutch medical doctor Ita Wegman , who established the first anthroposophic hospital in 1921 in Switzerland. Today AM is practiced in 80 countries worldwide. Anthroposophic physicians are fully trained and qualified doctors in academic medicine, but integrate conventional skills and methods with a holistic understanding of man and nature. Anthroposophical concepts of human beings in their entirety means the acceptance of a three-system organization with a physical body, the soul, and the spirit. This perspective on human beings leads to an understanding of health and illness that differs from conventional medicine, and to treatments that are specifically adapted to each individual [24, 25] . From the perspective of AM, use of B. pinnatum is indicated if the processes linked to psychic qualities, such as emotions, and the physiological processes are not well-balanced and, hence, disturb the basis for the healthy state of a patient. B. pinnatum is supposed to reunite these two parts of the human organization, thereby restoring holistic balance. Based on this concept, B. pinnatum has historically been used to treat inner restlessness and anxiety [26, 27] . Initially, B. pinnatum preparations were recommended by Steiner as anthroposophic medicines to treat "hysteria" [28, 29] .
In 1970, the German gynecologist Werner Hassauer (1928 Hassauer ( -1993 introduced B. pinnatum in the setting of an AM hospital as a tocolytic agent to prevent premature labor [30] .
Bryophyllum preparations and clinical uses:
In Germany, the use of B. pinnatum preparations is described in the monographs of the Commission C (former expert group on phytomedicines). In Switzerland, the use of B. pinnatum preparations is authorized by the Swiss Agency for therapeutic products (Swissmedic) as medicinal products without therapeutic indications and claims. B. pinnatum products are available in different galenical formulations. Main commercial products that are used include "Bryophyllum 50% powder" (containing leaf pressed juice adsorbed to lactose), "Bryophyllum chewable tablets 350 mg 50%" (leaf pressed juice adsorbed to lactose), "Bryophyllum Dilutio 33%" (ethanolic leaf extract) for oral application, and "Bryophyllum ampoules 5%" (acqueous leaf extract) for s.c. and i.v. administration. Globuli velati (sucrose globules coated with a syrup containing homeopathic dilutions) are also commercialized.
B. pinnatum preparations are currently used for the treatment of premature labor, and for some other medical conditions, such as sleep disorders induced by restlessness, anxiety, pain induced by vital weakness, and recurrent inflammation in the metabolic system [31] .
First clinical evidence was collected in a large multi-center observational study involving 38 German physicians collaborating in the Evaluation of Anthroposophic Medicine (EvaMed) network. Over six years, a total of 4038 prescriptions in a broad range of therapeutic indications were collected in the EvaMed data bank [32] . A recent online survey in Switzerland showed that in gynecology and obstetrics, "Bryophyllum chewable tablets" are being prescribed for pregnant women in the case of premature labor, and against restlessness and hyperactive bladder. With twothirds of the patients being treated at the University Hospital of Zurich, this survey showed that B. pinnatum is an herbal product which is no longer confined to anthroposophic medicine, and is meanwhile also used in conventional settings [33] .
Pharmacological and clinical activities related to uses in anthroposophic medicine: B. pinnatum has been used in anthroposophic medicine to treat various disorders caused by hyperactive conditions. Thus, pharmacological and clinical studies have mainly focused on these aspects.
B. pinnatum preparations have served as tocolytic agents for many years, and several studies have been performed. As mentioned above, the German gynecologist Dr. Hassauer showed that tocolysis with B. pinnatum 5% infusion (i.v.) and 50% trituration (p.o.) was well tolerated and successful in 84% of women. Treatment with
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Bryophyllum enabled him also to lower the dose of other medications, or even replace it [30] . A retrospective analysis from the obstetric clinic at the Hospital of Herdecke in Germany revealed good outcomes and fewer side-effects in patients treated with B. pinnatum only (n=89, ethanolic tincture 33%) compared to treatment with B. pinnatum and fenoterol (n=81) [34] . From 1977 to 2000, a total of 1622 deliveries were documented and evaluated by Dr. Istvan Vilàghy, a gynecologist who practiced in Switzerland. As of 1983, he integrated B. pinnatum into the treatment of premature labor, and treated pregnant women almost exclusively with B. pinnatum 33% dilution from 1990 to 2000. When using B. pinnatum the incidence of premature deliveries decreased to 1.1% [35] .
In a retrospective matched-pairs study involving sixty-seven pregnant women, the tolerability and tocolytic activity of B. pinnatum 5% (i.v.) was compared with beta-agonists (fenoterol or hexoprenaline). The study showed similar maternal and neonatal outcomes in both treatment groups. In the group receiving B. pinnatum, maternal adverse effects (palpitation, dyspnea) were significantly reduced, and the use of corticosteroids and antibiotics was lower. Neonatal outcomes and morbidity rates were similar or superior in the B. pinnatum treatment group [36] . A prospective, randomized clinical trial compared the efficacy and safety of B. pinnatum 50% chewable tablets with the calcium antagonist nifedipine in the treatment of premature contractions. Twenty-seven pregnant women were enrolled and treated in the study before it had to be interrupted due to slow recruitment. Nonetheless, data showed that B. pinnatum and nifedipine both significantly decreased the number of contractions/h, and that neonatal outcomes did not differ between the two groups [37] .
The tocolytic activity of B. pinnatum was confirmed by an in vitro study, in comparison to the standard medication fenoterol. B. pinnatum aqueous leaf extract (10 4 mg/L) led to a concentrationdependent inhibition of spontaneous human myometrium contractions, although the frequency of contractions increased. The extract also had a relaxant effect on oxytocin-induced contractions. Fenoterol decreased both myometrial contractions and frequency [38] . Next, the in vitro effects on spontaneous contractions in myometrial strips were investigated with B. pinnatum leaf pressed juice, and with three fractions of B. pinnatum methanolic leaf extract. The effects on the area under the curve (AUC), amplitude, and frequency of contractions were analyzed. The leaf press juice significantly lowered the AUC to 82% and rapidly increased the frequency to 128% after the first application. Reduction of the amplitude to 78% was statistically significant after the second application. The fraction enriched in flavonoids (undiluted) significantly reduced the AUC to 51% and caused a rapid and large increase in frequency to 557% after the first application. The amplitude was reduced to 70% after the second application. The other two fractions did not significantly affect the AUC and the amplitude, but increased the contraction frequency more than the control [39] .
The mechanism behind the tocolytic effect of B. pinnatum was further investigated using human myometrial cells. In hTERT-C3 cells, leaf pressed juice led to a concentration-dependent inhibition of the oxytocin-induced increase of intracellular [ ] i response to KCl was not lowered by the press juice but delayed, suggesting that the voltage-dependent calcium influx through the channels was restricted [40] .
Overactive bladder syndrome: Overactive bladder syndrome (OAB) is a symptomatic diagnosis that has been defined by the International Continence Society (ICS) as urinary urgency, with or without urge incontinence, usually with frequency and nocturia, after an exclusion of urinary tract infection (UTI) or other obvious pathologies [41] . Current pharmacotherapy includes drugs with various modes of action, such as muscarinic receptor antagonists which are currently the first-line pharmacotherapy for OAB and urinary incontinence. The beta3-agonist mirabegron with proven clinical benefits was recently approved in several countries, but only limited data on long-term efficacy and safety are available to date. Other drugs including calcium antagonists, serotonin and noradrenaline reuptake inhibitors, and estrogens, and intravesical injection of botulinum toxin are used to mitigate the symptoms of OAB.
In a prospective, randomized, double-blind, placebo-controlled study, 20 postmenopausal women suffering from OAB or urgencydominant mixed urinary incontinence (MUI) were treated with B. pinnatum 50% chewable tablets or placebo. The women took daily 3 x 2 blinded capsules during 8 weeks. After treatment, a positive trend for B. pinnatum was observed compared to placebo. The primary endpoint, the micturition frequency/24 h, was lowered from 9.5 before to 7.8 after the treatment (p=0.064), while the quality of life (QoL) was comparable in both groups [42] .
To afford an understanding of the possible pharmacological targets, the effect of B. pinnatum leaf pressed juice on porcine detrusor muscle contractility was investigated in an organ bath preparation, with oxybutynin as a reference drug. Compared to the control, pressed juice (5% in the chamber) significantly inhibited by 74.6% the detrusor contractility induced by electrical field stimulation (EFS). In addition, the pressed juice (10%) had a significant relaxant effect (18.7%) on carbachol-induced contractions. The leaf pressed juice showed good activity, although the inhibitory and relaxing properties of oxybutynin were more pronounced [43] .
The effect of leaf pressed juice and different fractions of B. pinnatum on electrically-induced porcine detrusor contractility was investigated in subsequent experiments. The inhibitory properties of the pressed juice were confirmed, even though an initial stimulatory effect was observed. A flavonoid-enriched fraction lowered muscle contractility in a concentration-and time-dependent manner, resulting in a maximum inhibition of 78.7% at a test concentration of 1 mg/mL after 77 min of treatment. In contrast, the bufadienolide-containing lipophilic fraction had no inhibitory effect on contractility at the concentrations used in the study. However, due to poor solubility the test concentrations were significantly lower than for the flavonoid-containing fraction [44] .
Sleep and neurological disorders:
In a prospective, multi-center observational study, forty-nine pregnant women suffering from sleep disorders were treated with "Bryophyllum chewable tablets". The women took 3 -8 tablets per day, and the number of wake-ups and subjective quality of sleep were recorded in a questionnaire before and after the 14-day treatment. Quality of sleep was significantly improved, and women felt less sleepy during the day. However, prolongation of sleep duration, and a lowering of the time to fall asleep were not achieved [45] . In a following study the effect of "Bryophyllum chewable tablets" on sleep quality was assessed in 1362 Natural Product Communications Vol. 12 (8) 2017 Hamburger et al. twenty cancer patients. Treatment (3 weeks) with chewable tablets (mostly 2 x 2 tablets per day) resulted in a decrease of the Pittsburg Sleep Quality Index (PSQI) from 12.2 to 9.1, and sleepiness was slightly reduced [46] .
The behavioral neuropharmacology of B. pinnatum aqueous leaf extract was investigated in mice, and sedative, CNS depressant, and anxiolytic activities were found. Furthermore, a significant and dose-dependent muscle relaxant effect of an aqueous leaf extract was observed. Therefore, GABAergic activity has been suggested for B. pinnatum [47] . Some of these neuropharmacological effects were tested in Swiss mice by administration of a methanolic extract from leaves. The GABA content in the brain was estimated after intraperitoneal (i.p.) administration, and the methanolic fraction led to an increase in brain GABA concentration [48] .
Compounds responsible for the neuropharmacological activity are not unambiguously identified at present. In the 1980's a neurosedative effect of bersaldegenin-1,3,5-orthoacetate (3) was demonstrated in mice, whereby strongly sedative activity was observed with doses of 0.1-0.5 mg/kg b.w. However, higher doses resulted in paralysis and muscle contractions [49] .
Tolerability of Bryophyllum preparations:
Good tolerability of B. pinnatum was reported in a retrospective and two randomized prospective clinical studies. In tocolysis, administration of B. pinnatum 5% i.v. and 50% p.o. resulted in fewer side effects than treatment with beta-mimetics. Specifically, occurrence of palpitations and dyspnea were significantly lower due to absence of effects on β 1 -adrenoceptors [36] . Treatment of fourteen pregnant women (Bryophyllum group) with "Bryophyllum chewable tablets" showed no side effects that were attributable to the medication [37] . A further study revealed no significant difference in observed side effects between treatment and control groups [42] .
In a longitudinal, prospective, randomized controlled animal study, the effect of the mother tincture (MT) 30% of B. pinnatum leaves in pregnant Wistar rats was investigated. From day 0 of gestation, 60 rats were treated with the B. pinnatum MT or pure vehicle. Two control groups, C1 and C2, were administered with an equivalent to the usual daily dose and 25-fold of the maximum daily dose of vehicle, respectively. Groups B1, B2, B3, and B4 received every day 1, 25, 50, and 100-fold of the maximum daily dose of MT, respectively. After 20 days of treatment, weight gain (excluding fetal and placental weight) was higher in group B4 than in groups B1, C2, and B2. However, the perinea in group C1 were heavier than those in group B2. No maternal or fetal deaths, no differences in implantations and resorptions, and no differences in the number and weight of fetuses and placentas were observed. External fetal abnormalities were not observed in groups B1-B4 [50] .
Toxicity of B. pinnatum:
Clinical experience over many years shows that B. pinnatum is well tolerated in patients. However, toxicity of Bryophyllum species has been reported to be related to bufadienolides, and was observed with animals grazing on B.
tubiflorum, B. daigremontianum, and B. pinnatum [8] . Cardiotoxicity of bersaldegenin-1,3,5-orthoacetate (3) was investigated in vitro using isolated rabbit and guinea pig hearts, and a strong positive inotropic effect was shown [51, 52] . An acute toxicity study was performed in rats which were given either a B. pinnatum methanolic extract from leaves, or distilled water as a single dose. A dose of 25 mg/kg b.w. caused neither death nor side effects, but the treatment with 200 mg/kg b.w. was lethal for 100% of animals [53] . Unfortunately, the information provided in the publication was incomplete and contradictory. In a similar study with Swiss albino mice, intraperitoneal administration of aqueous and methanolic extracts resulted in LD 50 values of 957 and 1159 mg/kg, respectively. Oral doses up to 3 g/kg b.w. in mice and rats led to no signs of toxicity [54] . In mice, an intraperitoneally administered methanolic extract from leaves led to no deaths up to 2500 mg/kg b.w., but to behavioral changes at concentrations higher than 100 mg/kg b.w. [55] .
Conclusion and outlook:
The introduction of B. pinnatum as an anthroposophic medicine was based on concepts of anthroposophy, and not on scientific grounds. Meanwhile, the use of B. pinnatum preparations as a tocolytic is supported by several clinical studies. Recent pharmacological investigations demonstrated effects on myometrial contraction, and also provided the first insights into the mode of action which appears to involve the oxytocin pathway. The overactive bladder syndrome, another "hyperactivity disease", may represent a new therapeutic indication for B. pinnatum preparations. As to sleep disorders, observational studies showed positive effects on restlessness in pregnant women and cancer patients. Controlled studies involving higher number of patients are needed to confirm these preliminary data. Even if the tocolytic activity and inhibition of detrusor contractibility could be linked to a flavonoid containing fraction, the phytochemicals responsible for these pharmacological and clinical effects of B. pinnatum are not yet fully clear. In particular, the exact contribution of bufadienolides and flavonoids to these different effects remains to be established. B. pinnatum was well tolerated in all clinical studies, and no serious side effects were observed. From a drug safety perspective, however, the quantity of bufadienolides in Bryophyllum preparations needs to be controlled, as some of these compounds have shown toxicity in animals, albeit at doses that were higher by several orders of magnitude than those found in pharmaceutical products. Current data confirm the potential of B. pinnatum for the treatment of "hyperactivity" disorders, but further studies are needed to fully understand the modes of action and to identify the active constituents, in order to provide further support for the rational clinical use of B. pinnatum.
